FDA Approves Tudriqev-Nivolumab Combo for Melanoma

The US Food and Drug Administration (FDA) has granted accelerated approval to vusolimogene oderparepvec-wtpg (Tudriqev; Replimune, Inc.), a genetically modified oncolytic viral therapy, in combination with nivolumab (Opdivo). This novel combination is indicated for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression on a programmed death receptor-1 (PD-1)-blocking antibody-based regimen.

For oncology nurses, this regulatory milestone introduces a new therapeutic class—oncolytic immunotherapy—into clinical advanced melanoma treatment workflows. Preparing clinical nursing teams for the adoption of this regimen requires a thorough understanding of the supporting clinical trials, complex localized dosing protocols, and strict biosafety handling requirements.

FDA Regulatory Actions and the Accelerated Pathway

The approval process for this first-in-class drug combination involved thorough federal safety and efficacy reviews:

• Advisory Committee Review: On July 30, 2026, the FDA convened the Cellular, Tissue, and Gene Therapies Advisory Committee Meeting to discuss the drug application. This public meeting featured a dedicated hearing section that allowed patients, patient advocates, clinicians, and independent experts to share clinical perspectives before committee deliberation.
• Accelerated Approval Framework: The FDA granted approval under its accelerated approval pathway based on objective response rate and duration of response. Continued approval for this indication may be contingent upon the verification and description of clinical benefit in confirmatory, post-approval clinical trials.
• Expedited Programs: The combination was granted breakthrough therapy designation, reflecting its potential clinical utility for patients who have exhausted traditional checkpoint inhibitors.

Supporting Efficacy and Safety Data from the IGNYTE Trial

Safety and efficacy were evaluated in the IGNYTE trial (NCT03767348), which served as the clinical foundation for this approval. Key trial characteristics and outcomes include:

• Trial Design: This open-label, multiregional, single-arm trial enrolled 140 adult patients with Stage IIIB, IIIC, or IV unresectable advanced melanoma. Every patient had documented disease progression on or after at least eight consecutive weeks of a prior anti-PD-1-based therapy.
• Efficacy-Evaluable Cohort: Of the 140 enrolled patients, 91 with at least one noninjected lesion were included in the primary efficacy-evaluable population.

Clinical Efficacy Results:

Major efficacy outcomes demonstrated:

• Objective Response Rate (ORR): An ORR of 24.2% (95% CI: 15.8%, 34.3%).
• Duration of Response (DOR): A median DOR of 14.1 months, with duration ranging from 10.7 months to not reached.

Nursing Dosing and Administration Guidelines

Oncolytic viral therapies require localized, intratumoral administration that differs significantly from standard intravenous immunotherapies. Nursing teams must strictly monitor and calculate the following administration parameters:

• Dosage Calculation: The recommended dosage of vusolimogene oderparepvec-wtpg is 1 mL/cm of the largest dimension of the target tumor.
• Lesion Assessment: Clinicians must physically assess and measure the size of each injectable lesion on every treatment day to calculate the required volume for that session.
• Dosing Cap: The total volume is strictly capped at a maximum of 10 mL across all treated lesions per individual dose.
• Lesion Prioritization: If multiple tumors exist, the clinical team should prioritize injecting the largest and most rapidly growing new or existing lesions.
• Injection Schedule: Intratumoral injections are administered every two weeks for a total of eight consecutive doses.
• Concentration Titration: Treatment starts at a concentration of 10⁶ plaque-forming units (PFU) per mL at Week 1, followed by an escalation to 10⁷ PFU/mL for all subsequent doses.
• Nivolumab Timing: Intravenous nivolumab begins later at Week 3 and is administered according to its standard prescribing information.

Nursing Safety Precautions and Monitoring Priorities

Because this is a live, genetically modified viral therapy, oncology nurses are responsible for strict biosafety adherence and proactive symptom management. The prescribing information contains warnings for:

• Accidental Exposure: Nurses must follow standard institutional biosafety protocols for handling viral therapies to prevent exposure of healthcare staff or patient contacts.
• Herpetic Infection: Clinical monitoring for signs of herpetic infection or viral reactivation is required.
• Injection Complications: Teams must monitor patients for localized complications resulting from the injection procedure.
• Immune-Mediated Events: Nurses must monitor for systemic immune-mediated adverse events associated with combining oncolytic viruses with checkpoint inhibitors.
• Adverse Reactions: Common non-laboratory adverse reactions reported in more than 10% of patients include fatigue, pyrexia, infections, chills, musculoskeletal pain, nausea, diarrhea, injection site reaction, headache, cough, influenza-like illness, rash, vomiting, pruritus, arthralgia, constipation, decreased appetite, dizziness, dyspnea, hemorrhage, edema, and abdominal pain.
• Safety Reporting: Suspected serious adverse events should be reported to the FDA's MedWatch Reporting System at 1-800-FDA-1088 or online.
• Single-Patient Use: For assistance with single-patient IND requests, healthcare professionals may contact OCE's Project Facilitate at 240-402-0004 or [email protected].

Reference

US Food and Drug Administration. FDA grants accelerated approval to vusolimogene oderparepvec-wtpg in combination with nivolumab for melanoma. FDA website. Published August 6, 2026. Accessed August 6, 2026. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-vusolimogene-oderparepvec-wtpg-combination-nivolumab-melanoma